Stock Scorecard



Stock Summary for Rigel Pharmaceuticals (RIGL) - $24.31 as of 11/20/2024 8:38:57 PM EST

Total Score

9 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for RIGL

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for RIGL

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for RIGL

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for RIGL

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for RIGL (34 out of 90)

Stock Price Rating (Max of 10) 7
Historical Stock Price Rating (Max of 10) 8
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 2
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 5
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 2

Latest News for for RIGL

How Much Upside is Left in Rigel ( RIGL ) ? Wall Street Analysts Think 28.28% 11/19/2024 2:55:00 PM
5 Relative Price Strength Options Available for Investors 11/18/2024 8:00:00 PM
Rigel Pharmaceuticals ( RIGL ) Q3 Earnings and Revenues Top Estimates 11/7/2024 10:15:00 PM
BPMC Beats on Q3 Earnings and Sales, Raises '24 View, Stock Up 10/31/2024 12:45:00 PM
Neurocrine Biosciences ( NBIX ) Q3 Earnings Miss Estimates 10/30/2024 12:10:00 PM
Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE® - Rigel Pharmaceuticals ( NASDAQ:RIGL ) 10/16/2024 2:00:00 PM
Rigel ( RIGL ) Surges 19.7%: Is This an Indication of Further Gains? 9/25/2024 8:34:00 AM
Rigel Pharmaceuticals ( RIGL ) Reports Q2 Loss, Tops Revenue Estimates 8/6/2024 9:30:00 PM
Profound Medical ( PROF ) Expected to Beat Earnings Estimates: Can the Stock Move Higher? 8/1/2024 2:01:00 PM
Aurinia Pharmaceuticals ( AUPH ) Q2 Earnings and Revenues Beat Estimates 8/1/2024 11:10:00 AM

Financial Details for RIGL

Company Overview

Ticker RIGL
Company Name Rigel Pharmaceuticals
Country USA
Description Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is headquartered in South San Francisco, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 24.31
Price 4 Years Ago 35.00
Last Day Price Updated 11/20/2024 8:38:57 PM EST
Last Day Volume 168,437
Average Daily Volume 216,788
52-Week High 29.82
52-Week Low 7.48
Last Price to 52 Week Low 225.00%

Valuation Measures

Trailing PE 84.22
Industry PE 22.60
Sector PE 40.32
5-Year Average PE -115.16
Free Cash Flow Ratio 7.01
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 1.96
Total Cash Per Share 3.47
Book Value Per Share Most Recent Quarter -0.83
Price to Book Ratio 31.64
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 2.55
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 1
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 17,615,000
Market Capitalization 428,220,650
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 1.33%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY -47.90%
Annual Earnings Growth 57.16%
Reported EPS 12 Trailing Months 0.27
Reported EPS Past Year 0.59
Reported EPS Prior Year -0.15
Net Income Twelve Trailing Months 3,881,000
Net Income Past Year -25,091,000
Net Income Prior Year -58,573,000
Quarterly Revenue Growth YOY 96.60%
5-Year Revenue Growth 19.93%
Operating Margin Twelve Trailing Months 0.25

Balance Sheet

Total Cash Most Recent Quarter 61,114,000
Total Cash Past Year 56,933,000
Total Cash Prior Year 58,206,000
Net Cash Position Most Recent Quarter 1,114,000
Net Cash Position Past Year -3,067,000
Long Term Debt Past Year 60,000,000
Long Term Debt Prior Year 40,000,000
Total Debt Most Recent Quarter 60,000,000
Equity to Debt Ratio Past Year -0.91
Equity to Debt Ratio Most Recent Quarter -0.32
Total Stockholder Equity Past Year -28,644,000
Total Stockholder Equity Prior Year -13,616,000
Total Stockholder Equity Most Recent Quarter -14,636,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 10,368,000
Free Cash Flow Per Share Twelve Trailing Months 0.59
Free Cash Flow Past Year -20,743,000
Free Cash Flow Prior Year -74,208,000

Options

Put/Call Ratio 1.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 2.60
MACD Signal 1.08
20-Day Bollinger Lower Band 5.13
20-Day Bollinger Middle Band 13.89
20-Day Bollinger Upper Band 22.65
Beta 0.95
RSI 91.58
50-Day SMA 12.53
150-Day SMA 14.43
200-Day SMA 20.10

System

Modified 11/19/2024 11:32:35 AM EST